ANI Pharmaceuticals, Inc.
$81.73
▼
-2.3%
2026-04-21 05:19:00
www.anipharmaceuticals.com
NGM: ANIP
Explore ANI Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.81 B
Current Price
$81.73
52W High / Low
$99.5 / $56.71
Stock P/E
23.13
Book Value
$25.8
Dividend Yield
0.06%
ROCE
6.99%
ROE
16.16%
Face Value
—
EPS
$3.32
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
970
Beta
0.43
Debt / Equity
116.19
Current Ratio
2.71
Quick Ratio
2.19
Forward P/E
7.45
Price / Sales
2.02
Enterprise Value
$1.97 B
EV / EBITDA
11.27
EV / Revenue
2.23
Rating
Buy
Target Price
$110.62
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Short-term liquidity looks comfortable.
Cons
- Capital efficiency is modest.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Canopy Growth Corporation | $1.2 | — | $709.79 M | — | -8.06% | -48.5% | $3.28 / $1.18 | $1.49 |
| 2. | Emergent BioSolutions Inc. | $8.35 | 8.47 | $445.43 M | — | 9.47% | 10.46% | $14.06 / $4.45 | $10.03 |
| 3. | Gelteq Limited | $0.7 | — | $7.5 M | — | -31.25% | -42.99% | $4.11 / $0.64 | $1.09 |
| 4. | Pacira BioSciences, Inc. | $24.9 | 143.33 | $1.01 B | — | 2.91% | 0.96% | $27.64 / $18.8 | $16.86 |
| 5. | Hims & Hers Health, Inc. | $28.91 | 56.32 | $6.55 B | — | 6.03% | 25.23% | $70.43 / $13.74 | $2.38 |
| 6. | InterCure Ltd. | $0.75 | — | $125.93 M | — | -8.41% | -16.68% | $605 / $225.3 | $7.59 |
| 7. | Bausch Health Companies Inc. | $5.91 | 14.05 | $3.02 B | — | 9.85% | 4.36% | $11.97 / $6.06 | $-1.5 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 247.06 M | 227.81 M | 211.37 M | 197.12 M | 190.57 M | — |
| Operating Profit | 29.13 M | 22.83 M | 15.17 M | 14.1 M | 1.33 M | — |
| Net Profit | 27.49 M | 26.62 M | 8.55 M | 15.68 M | -10.28 M | — |
| EPS in Rs | 1.21 | 1.17 | 0.38 | 0.69 | -0.45 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 883.37 M | 614.38 M | 486.82 M | 316.38 M |
| Operating Profit | 81.23 M | 2.22 M | 49.53 M | -25.73 M |
| Net Profit | 78.34 M | -18.52 M | 18.78 M | -47.9 M |
| EPS in Rs | 3.44 | -0.81 | 0.83 | -2.11 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.44 B | 1.28 B | 904.42 M | 760.09 M |
| Total Liabilities | 899.65 M | 855.94 M | 446.82 M | 421.55 M |
| Equity | 540.72 M | 428.53 M | 457.6 M | 338.54 M |
| Current Assets | 753.12 M | 528.46 M | 519.82 M | 344.26 M |
| Current Liabilities | 278.11 M | 194.45 M | 145.48 M | 99.44 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 185.22 M | 64.02 M | 118.96 M | -31.2 M |
| Investing CF | -34.32 M | -404.72 M | -18.51 M | -15.74 M |
| Financing CF | -9.94 M | 264.94 M | 67.44 M | -5.13 M |
| Free CF | 150.9 M | 47.06 M | 100.45 M | -47.66 M |
| Capex | -34.32 M | -16.95 M | -18.51 M | -16.45 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 26.2% | 53.87% | — | — |
| Earnings Growth % | -198.63% | 139.21% | — | — |
| Profit Margin % | -3.01% | 3.86% | -15.14% | — |
| Operating Margin % | 0.36% | 10.17% | -8.13% | — |
| Gross Margin % | 59.27% | 62.71% | 56.13% | — |
| EBITDA Margin % | 10.27% | 21.9% | 7.91% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.